Sargent Bickham Lagudis LLC Arcturus Therapeutics Holdings Inc. Transaction History
Sargent Bickham Lagudis LLC
- $1.22 Billion
- Q4 2022
A detailed history of Sargent Bickham Lagudis LLC transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Sargent Bickham Lagudis LLC holds 100 shares of ARCT stock, worth $727. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100
Previous 100
-0.0%
Holding current value
$727
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ARCT
# of Institutions
173Shares Held
26MCall Options Held
2.32MPut Options Held
866K-
Federated Hermes, Inc. Pittsburgh, PA4.69MShares$34.1 Million0.16% of portfolio
-
Black Rock Inc. New York, NY2.65MShares$19.3 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.1.95MShares$14.2 Million0.39% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.1.95MShares$14.2 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.89MShares$13.7 Million0.0% of portfolio
About Arcturus Therapeutics Holdings Inc.
- Ticker ARCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,576,400
- Market Cap $193M
- Description
- Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...